Seamless Endocrinology Olive AI Replacement for Prior Authorization

For endocrinology practices navigating an Olive AI replacement, Klivira offers a purpose-built prior authorization automation platform designed to ensure continuity and efficiency for high-volume treatments.

The discontinuation of Olive AI's prior authorization solution presents a critical need for seamless migration, particularly for specialties with complex and high-volume PA requirements like endocrinology. Revenue cycle leaders and PA coordinators must secure a replacement that integrates deeply with existing EMRs and effectively manages the nuances of diabetes and metabolic disorder treatments.

Addressing the Endocrinology Olive AI Replacement Challenge

The transition from a prior authorization platform like Olive AI demands a strategic approach, especially for endocrinology where PA volumes for GLP-1s, CGMs, and insulin pumps are substantial. Klivira provides a robust, EMR-integrated solution to ensure uninterrupted PA workflows, minimizing disruption to patient care and revenue streams during this critical migration.

Critical Prior Authorization Categories in Endocrinology

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for T2D and obesity, including dual GIP/GLP-1s.
SGLT2 inhibitors (e.g., empagliflozin) for T2D, heart failure, and CKD indications.
Continuous Glucose Monitoring (CGM) systems like Dexcom G7 and FreeStyle Libre 3.
Insulin pumps and tubeless systems (e.g., Tandem t:slim X2, Omnipod 5).
Growth hormone therapy, including somatropin biosimilars.

Streamlining Documentation for Endocrinology PAs

Endocrinology prior authorizations are heavily guided by clinical frameworks such as ADA Standards of Care, AACE Clinical Practice Guidelines, and ATA Guidelines. Klivira's platform is engineered to support these requirements, automating the collection of essential data points like A1c, BMI, eGFR, and documentation of prior medication trials or lifestyle interventions directly from the EMR.

Mitigating Common Prior Authorization Denials in Endocrinology

GLP-1 obesity-indication coverage gaps and restrictive payer criteria.
Failure to meet step therapy requirements for GLP-1 RAs in T2D.
CGM denials for T2D patients not requiring insulin.
Payer requirements for biosimilar substitution for insulin and growth hormone.
Insufficient documentation of BMI criteria or patient compliance for ongoing device coverage.

Klivira's EMR-Integrated Solution for Endocrinology PA Automation

Klivira provides an advanced platform to manage the unique workflow constraints of endocrinology, including high GLP-1 PA volumes, recurring CGM re-authorization cycles, and the coordinated PA process for hybrid closed-loop systems. Our integration capabilities ensure that patient data flows seamlessly, supporting payer-specific obesity medication coverage variability and specialty-pharmacy fulfillment.

Ensuring Continuity Post-Olive AI for Endocrinology Workflows

Replacing a prior authorization system like Olive AI requires a solution that not only matches previous capabilities but enhances them. Klivira’s platform offers robust payer connectivity and EMR integration, including SMART on FHIR capabilities, to ensure that endocrinology practices can maintain efficient PA processing, reduce administrative burden, and minimize revenue cycle interruptions.

Frequently asked questions

How does Klivira specifically handle GLP-1 prior authorizations, given their high volume and complex criteria?

Klivira's platform incorporates ADA/AACE-guideline-aware step-therapy logic and indication-specific routing for GLP-1s (T2D vs. obesity). It automates the collection of required documentation, such as A1c and prior medication trials, directly from your EMR to streamline submissions and reduce manual effort.

What is Klivira's approach to replacing Olive AI for CGM and insulin pump re-authorizations?

Klivira manages the periodic re-authorization cycles for CGMs and insulin pumps, including adherence documentation, which is critical for ongoing coverage. Our system automates the re-submission process, ensuring that coordinated CGM + pump PA workflows are maintained without disruption after migrating from Olive AI.

Can Klivira integrate with our existing EMR to pull endocrinology-specific clinical data for PAs?

Yes, Klivira integrates with leading EMRs, leveraging standards like SMART on FHIR, to automatically extract relevant endocrinology data such as A1c levels, BMI, eGFR, and documentation of prior therapies. This capability significantly reduces manual data entry and improves the accuracy of prior authorization submissions.

How does Klivira address the variability in payer coverage for obesity medications like Zepbound or Wegovy?

Klivira's policy engine tracks and adapts to payer-specific obesity benefit statuses and coverage criteria, which can vary widely and change frequently. The platform helps identify if an obesity indication is covered for a specific payer and member, guiding the PA process accordingly to minimize denials.

What steps does Klivira take to ensure a smooth transition for endocrinology practices migrating from Olive AI?

Klivira offers a structured migration process focused on continuity. We work with your team to map existing workflows, configure our platform to your specific endocrinology PA needs, and integrate seamlessly with your EMR, ensuring minimal disruption to your revenue cycle and patient care during the Olive AI replacement.